Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010

Drug Discovery Today

Volumn 17, Issue 15-16, 2012, Pages 898-904

  Pariser, Anne R ^a   Slack, Daniel J ^a   Bauer, Larry J ^a   Warner, Catherine A ^a   Tracy, Laree A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CARCINOMA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; MYELOID LEUKEMIA; POSTMARKETING SURVEILLANCE; PRODUCT DEVELOPMENT; PRODUCT SAFETY; RARE DISEASE; REVIEW;

DRUG APPROVAL; HUMANS; MARKETING; RARE DISEASES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84864628576     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.04.011     Document Type: Review

References (33)

1. M.J. Field, and T.F. Boat Rare Diseases and Orphan Products: Accelerating Research and Development 2010 The National Academies Press
2. M.E. Haffner Two decades of orphan product development Nat. Rev. Drug Discov. 1 2002 821 825 (Pubitemid 37361565)
3. R.C. Griggs For the rare diseases clinical research network. Clinical research for rare disease: opportunities, challenges, and solutions Mol. Genet. Metab. 96 2009 20 26
4. M.M. Braun Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years Nat. Rev. Drug Discov. 9 2010 519 522
5. Orphan Drug Act, Pub. L. 97-414. 96 Stat. 2049 (1983). Amended in 1984 by Pub. L. 98-551 to add a numeric prevalence threshold to the definition of rare diseases
6. US Food and Drug Administration Code of Federal Regulations Title 21: Approval of an Application and an Abbreviated Application. Pt314.105 2011 US Government Printing Office
7. US Food and Drug Administration (2011). Search orphan drug designation and approvals. (Accessed, 25 April, 2012, at: http://www.accessdata.fda.gov/ scripts/opdlisting/oopd/index.cfm)
8. M.E. Haffner Adopting orphan drugs - two dozen years of treating rare diseases N. Engl. J. Med. 354 2006 445 447 (Pubitemid 43200295)
9. A.S. Kesselheim Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer JAMA 305 2011 2320 2326
10. J. Mitsumoto Pivotal studies of orphan drugs approved for neurological diseases Ann. Neurol. 66 2009 184 190
11. Sasinowski, F.J. (2011) Quantum of Effectiveness in FDA's Approval of Orphan Drugs. Cataloguing FDA's Flexibility in Regulating Therapies for Persons with Rare Disorders. (Accessed, 25 April, 2012, at: http://www.rarediseases.org/ docs/policy/NORDstudyofFDAapprovaloforphandrugs.pdf)
12. US Food and Drug Administration Guidance for Industry. Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products 1998
13. Institute of Medicine Committee on Accelerating Rare Diseases Research and Orphan Product Development, Board on Health Sciences Policy Regulatory framework for drugs for rare diseases M.J. Field, T.F. Boat, Rare Diseases and Orphan Products: Accelerating Research and Development, 2010 The National Academies Press 73 110
14. Federal Food, Drug, and Cosmetic Act (FD&C Act), Section 505(b) [21 USC §355]. New Drugs. As amended through December 31, 2004
15. US Food and Drug Administration. News and Events, July 9, 2008. (Accessed, 25 April, 2012, at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2008/ucm116920.htm)
16. US Food and Drug Administration. Complete Response Letter Final Rule, July 9, 2008. (Accessed, 25 April, 2012, at: http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/LawsActsandRules/ucm084138.htm)
17. US Food and Drug Administration Code of Federal Regulations Title 21: Filing an Application and Receiving an Abbreviated New Drug Application. Pt314.101 2011 US Government Printing Office
18. Dagher, R. and Justice, R. (2006) Summary review of NDA, 21938 gastrointestinal stromal tumors (GIST), 21968 renal cell cancer (RCC). Search US Food and Drug Administration Drugs@FDA. (Accessed, 25 April, 2012, at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm ['sunitinib'])
19. H.E. Heemstra Characteristics of orphan drug applications that fail to achieve marketing approval in the USA Drug Discov. Today 16 2011 73 80
20. US Food and Drug Administration. Search internal orphan drug designation and approvals (not publically accessible). (Accessed January through July, 2011)
21. US Food and Drug Administration Code of Federal Regulations Title 21: Meetings. Pt 312.47 2011 US Government Printing Office
22. H.E. Heemstra Predictors of orphan drug approval in the European Union Eur. J. Clin. Pharmacol. 64 2008 545 552
23. S.S. Talele Therapies for inborn errors of metabolism: what has the Orphan Drug Act delivered? Pediatrics 126 2010 101 106
24. M. Putzeist Determinants for successful marketing authorization of orphan medicinal products in the ER Drug Discov. Today 17 2012 352 358
25. J. Regnstrom Factors associated with success of market authorization applications for pharmaceutical drugs submitted to the European Medicines Agency Eur. J. Clin. Pharmacol. 66 2010 39 48
26. I. Melnikova Rare diseases and orphan drugs Nat. Rev. Drug Discov. 11 2012 267 268
27. US Food and Drug Administration (1992). Prescription Drug User Fee Act (PDUFA). Standard Review and Priority Review. (Accessed, 25 April, 2012, at: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ SpeedingAccesstoImportantNewTherapies/ucm128291.htm)
28. FDA, CDER Manual of Policies and Procedures (MAPP) 6020.3, Priority Review, July 16, 2007. (Accessed, 25 April, 2012, at: http://www.fda.gov/ downloads/AboutFDA/CentersOffices/CDER/ManualofPoliciesProcedures/ucm082000.pdf)
29. M. Putzeist Regulatory scientific advice in drug development: does company size make a difference? Eur. J. Clin. Pharmacol. 67 2011 157 164
30. M. Wastfelt A journey of hope: lessons learned from studies on rare diseases and orphan drugs J. Intern. Med. 260 2006 1 10 (Pubitemid 43894064)
31. P. Stolk "Rare essentials": drugs for rare diseases as essential medicines Bull. World Health Organ. 84 2006 745 751 (Pubitemid 44482401)
32. P.I. Dickson Research challenges in central nervous system manifestations of inborn errors of metabolism Mol. Genet. Metab. 102 2010 326 338
33. Castellani, J.J. (2011) Report. Orphan Drugs in Development for Rare Diseases. More than 400 Medicines in Development to Treat or Prevent Rare Diseases. (Accessed, 25 April, 2012, at: http://www.phrma.org/sites/default/ files/878/rarediseases2011.pdf)